This phase I/II trial is evaluating a new drug (BGB-290) in combination with an oral chemotherapy drug (Temozolomide) in patients with locally advanced or metastatic solid cancers.
This trial is treating patients with advanced solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have been diagnosed with a prior or secondary type of cancer.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
BeiGene USA, Inc.
This is a non-randomised dose escalation and expansion study. Patients will be assigned to one of three arms. In Arm A (Dose Escalation) approximately 25 patients will receive continuous BGB-290 and TMZ on Days 1-7 of a 28 day cycle. In Arm B (Dose Escalation) approximately 25 patients will receive continuous BGB-290 and continuous TMZ on a 28 day cycle. In Arm C (Dose Expansion) approximately 100 patients will receive BGB-290 and TMZ at the recommended dose from the escalation phase.
Not Recruiting Hospitals Read More